• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » opioid use disorder

Articles Tagged with ''opioid use disorder''

TCPR-Oct2024_QA_NCapurso headshot.png
Clinical Update

A New Era for Buprenorphine

September 26, 2024
Noah Capurso, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

TCPR-Oct2024_QA_NCapurso headshot.pngNoah Capurso, MD, MHS.

Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Capurso has no financial relationships with companies related to this material.

A buprenorphine boot camp for all who need to know how to use it in the post-X-waiver age.


Read More
Clinical Update

Post X-Waiver Buprenorphine Prescribing

September 26, 2024
Noah Capurso, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Capurso has no financial relationships with companies related to this material.

All clinicians need to know how to use buprenorphine under the DEAs new regulations. Meanwhile, the fentanyl crisis is changing how we use it. Noah Capurso shows us how to navigate these waters.


Read More
Research Update

Buprenorphine Versus Methadone for Opioid Use Disorder in Pregnancy

July 1, 2024
Richard Moldawsky, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.

Buprenorphine and methadone are both first-line treatments for opioid use disorder during pregnancy. Though this recommendation has been long-standing, it is based on a rather small study that is nearly 15 years old. In the current study, researchers revisit the question of how best to treat opioid use disorder during pregnancy with a large observational cohort study.


Read More
gavel_AlexStaroseltsev_shutterstock_404793811.jpg
Expert Q&A

Opioid Use Disorder in Correctional Facilities

July 1, 2024
Elizabeth Needham Waddell, PhD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

CATR_QA2-Elizabeth-Needham-Waddell_headshot.jpgElizabeth Needham Waddell, PhD. 

Associate Professor, OHSU-PSU School of Public Health & Section of Addiction Medicine, Division of General Internal Medicine, Oregon Health & Science University, Portland, OR.

Dr. Waddell has no financial relationships with companies related to this material.

People with opioid use disorder who are incarcerated have an elevated rate of morbidity and mortality, particularly following release.


Read More
Research Update

Opioid Use Disorder Treatment During the Peripartum Period

April 1, 2024
Gregory Nikogosyan, DO
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Gregory Nikogosyan, DO. Dr. Nikogosyan has no financial relationships with companies related to this material.

The last high-quality head-to-head comparison of buprenorphine and methadone during pregnancy was the MOTHER trial, which was published nearly 15 years ago. Here, researchers revisited the question of which medication is better to use in pregnancy in this large, carefully done, retrospective study. The results make a compelling case for buprenorphine. 


Read More
Research Update

Extended-Release Buprenorphine for Opioid Use Disorder in Correctional Settings

February 1, 2024
Eli Neustadter, MD, MSc.
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Eli Neustadter, MD, MSc. Dr. Neustadter has no financial relationships with companies related to this material.

Incarcerated individuals with opioid use disorder are at an especially heightened risk of adverse outcomes.  The period immediately following release is a particularly vulnerable time, with a much elevated risk of fatal overdose. In this study, investigators report on the use of extended-release injectable buprenorphine in a correctional setting.


Read More
Research Update

Perinatal MOUD Use and Infant Discharge to Biological Parents

October 31, 2023
Destiny Pegram, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Destiny Pegram, MD. Dr. Pegram has no financial relationships with companies related to this material.

Pregnant patients with OUD may be reluctant to reveal their substance use for fear of losing their baby if reported to Child Protective Services. But this recent study shows that pregnant patients receiving medication treatment for OUD were more likely to leave the hospital with their baby than patients not receiving treatment.


Read More
CATR_JulAugSept_cover_shutterstock_1572207760.jpg
Expert Q&A

The State of Opioids on the Street

May 29, 2023
Daniel Ciccarone, MD, MPH
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

CATR_QA1_headshot_DanielCiccarone.jpgDaniel Ciccarone, MD, MPH. 

Justine Miner Professor of Addiction Medicine at the University of California San Francisco.

Dr. Ciccarone is a member of the scientific advisory board for Celero Systems. Relevant financial relationships listed for the author have been mitigated.

Dr. Ciccarone sheds light on the current chaotic and perilous situation surrounding illicit opioids found on the streets.


Read More
Clinical Update

Medication Treatments for Alcohol and Opioid Use Disorder in Older Adults

May 11, 2023
Rehan Aziz, MD.
From The Carlat Geriatric Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Rehan Aziz, MD. Associate program director, Geriatric Psychiatry Fellowship Program, Jersey Shore University Medical Center, Neptune, NJ; associate professor of psychiatry and neurology, Hackensack Meridian School of Medicine, Nutley, NJ.

Dr. Aziz has no financial relationships with companies related to this material.

With three FDA-approved medications for alcohol use disorders and three FDA-approved medications for opioid use disorders, it can be hard to know where to start. Here we review the pros and cons of these six medications—and provide recommendations for their use in older adults.


Read More
Expert Q&A

Management of Chronic Pain

April 1, 2023
Lewei (Allison) Lin, MD, MS
From The Carlat Hospital Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

QA2_PainMgmt_Lin_headshot_gry_headshot.jpgLewei (Allison) Lin, MD, MS. Associate professor, Department of Psychiatry, University of Michigan Medical School; research scientist, Center for Clinical Management Research, VA Ann Arbor Healthcare System. Ann Arbor, MA.

Dr. Lin has served as a consultant for the National Committee for Quality Assurance via a grant from Alkermes. Relevant financial relationships listed for the author have been mitigated.

Patients with psychiatric conditions are more likely than other patients to experience chronic pain and to receive opioid prescriptions. Dr. Lin shares her holistic approaches to pain management that incorporate psychosocial, psychotherapeutic, and psychopharmacologic treatments.


Read More
Previous 1 2 3 4 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2730546171.jpg
    General Psychiatry

    ProLivRx: How it Works

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.